GS 9876

Drug Profile

GS 9876

Alternative Names: GS-9876

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antirheumatics
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 17 Mar 2017 Gilead Sciences plans a phase II trial for Rheumatoid arthritis (Combination therapy) (Gilead Sciences 10-K, February 2017)
  • 11 Nov 2016 Pharmacokinetics and adverse events data from a phase I trial (In volunteers) presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR-ARHP-2016)
  • 11 Nov 2016 Pharmacokinetics and pharmacodynamics data from a preclinical study in Arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top